Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease that has no established cure and is frequently fatal within 2 to 5 years as patients experience a rapid functional decline in their abilities to move, talk, swallow, and breathe. Current treatment options remain limited, but there is a pipeline of late-stage therapeutic options that could expand the treatment options for patients with ALS.